comparemela.com

Latest Breaking News On - National medical products - Page 22 : comparemela.com

China NMPA Approves TYVYT (sintilimab) In Combination With Chemotherapy For Gastric Cancer - Life Sciences, Biotechnology & Nanotechnology

On June 24, 2022, Innovent Biologics, Inc. and Eli Lilly and Company announced that the National Medical Products Administration (NMPA) of China approved the supplemental New Drug Application (sNDA) for.

Eli lillyNational medical productsInnovent biologics incInnovent biologicsNew drugChina nmpa approves tyvyt sintilimab in combination with chemotherapy for gastric cancerLife sciencesLife sciencesIotechnology amp nanotechnology

Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18 2/CD47 bsAb clinical trial application

/PRNewswire/ On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection.

Guilin sanjinGuojun langNational medical products administrationSanyou cooperative project organizationSanyou biopharmaceuticals co ltdDragon boatNational medical productsCooperative project organizationDragon boat pharmaceuticalSanyou biopharmaceuticalsHealth care amp hospitalsMedical pharmaceuticals

Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18 2/CD47 bsAb clinical trial application - Press Release

SHANGHAI, June 25, 2022 /PRNewswire/ On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-spec

Guilin sanjinGuojun langNational medical products administrationSanyou cooperative project organizationSanyou biopharmaceuticals co ltdDragon boatNational medical productsCooperative project organizationDragon boat pharmaceutical

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing

United statesFoster cityJacquie rossTaiyin yangStacey maYale universityGilead sciencesDrug administrationGilead sciences incGilead pharmaceutical developmentChina national medical products administrationTechnology in genentech roche pharma technical operationsGilead on twitter sciencesGilead public affairsEuropean medicines agencyAmerican institute for

Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and

– Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead –FOSTER CITY, Calif. (BUSINESS WIRE) Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development a.

United statesFoster cityJacquie rossTaiyin yangStacey maYale universityGilead sciencesDrug administrationGilead sciences incGilead pharmaceutical developmentChina national medical products administrationTechnology in genentech roche pharma technical operationsGilead on twitter sciencesGilead public affairsEuropean medicines agencyAmerican institute for

vimarsana © 2020. All Rights Reserved.